Clinical Trials
10 trialsNCT05581004 2026-05-11
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT04540211 2026-04-09
SKYSCRAPER-08
Hoffmann-La Roche
Phase 3 Completed
NCT03281369 2025-12-15
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
Hoffmann-La Roche
Phase 1/2 Completed
NCT04166721 2025-04-06
WaKING: Wnt and checKpoint INhibition in Gastric Cancer
Royal Marsden NHS Foundation Trust
Phase 1/2 Active not recruiting
NCT03829501 2025-04-02
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Kymab Limited
Phase 1/2 Terminated
NCT02876510 2025-02-04
ACTolog
Immatics US, Inc.
Phase 1 Completed
NCT05007613 2025-01-01
Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
National Taiwan University Hospital
Phase 2 Completed
NCT03544723 2020-06-09
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Phase 2 Unknown
NCT03087864 2020-05-11
PERFECT
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Completed
NCT03818997 2020-02-05
DYNAMIC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn